ID: h-0d597b942f
Hypothesis

Perturbation-first validation should precede therapeutic claims for m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra

The debate supports treating this as a validation program before ranking it as a therapy.
🧬 N6-🩺 neurodegeneration🎯 Composite 61%💱 $0.56▼8.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 1 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.63 (15%) Evidence 0.55 (15%) Novelty 0.60 (12%) Feasibility 0.76 (12%) Impact 0.57 (12%) Druggability 0.48 (10%) Safety 0.60 (8%) Competition 0.55 (6%) Data Avail. 0.68 (5%) Reproducible 0.66 (5%) KG Connect 0.50 (8%) 0.608 composite

🧪 Overview

The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["m6A RNA Modification<br/>Alpha-Synuclein Transcript Fate Control"]
    B["Perturbation-First Validation Required<br/>METTL3/METTL14 Manipulation"]
    C["m6A Epitranscriptomic Editing<br/>CasRx or small molecule inhibition"]
    D["SNCA Aggregation Phenotype<br/>PD Model Systems Testing"]
    E["Mechanism Validation<br/>Confirm m6A-SNCA-Aggregation Axis"]
    F["PD Therapeutic Target<br/>m6A Writer Complex as Intervention Point"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#4a148c,stroke:#ce93d8,color:#ce93d8
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix1 supports1 contradicts
Supports
The proposed priority experiment is concrete: dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays
Contradicts
Therapeutic tractability is not established by the current source evidence.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — N6-

No curated PDB or AlphaFold mapping for N6- yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for N6- →

No DepMap CRISPR Chronos data found for N6-.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.7%
Volatility
Low
0.0016
Events (7d)
3
Price History
▼8.4%

💾 Resource Usage

LLM Tokens
492,603
$1.8154
API Calls
302
Total Cost
$1.8154
Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.